华南地区鲍曼不动杆菌流行株的毒力变迁研究

来源期刊：广州医药 | 91-96 发布时间：2023-04-14 收稿时间：2025/11/13 18:37:48 阅读量：23

作者：: 曾军,

卓超,

杨智,

苏伟,

唐翔,

关键词：: 鲍曼不动杆菌 ST457 毒力; Acinetobacter baumannii" style="padding-right:10px">Acinetobacter baumannii')">Acinetobacter baumanniiST457 virulence

DOI：: 10.3969/j.issn.1000-8535.2023.03.017

收稿时间：: 2022-09-01
修订日期：
接收日期：
引用总数：: 0

目的探讨我国南方地区鲍曼不动杆菌流行株ST457毒力进化方向。方法收集南方地区5家大型三甲医院2012年—2015年血和/或痰标本来源的鲍曼不动杆菌菌株,运用不同毒力实验,比较ST457与其他CC92流行克隆株与非流行克隆株的毒力差异。结果 ST457感染患者早期死亡率高;ST457菌株平均产生物膜能力低于ST195和ST208;83.3%的鲍曼不动杆菌临床分离菌株在血清的存活率大于60%,其中43.3%的菌株可在血清内快速繁殖,不同ST型组间、菌血症组和非菌血症组间无差异;不同ST型菌株竞争后,ST457未展现出竞争优势。结论与传统CC92流行株相比,ST457毒力表型与传统的CC92流行株类似,提示CC92克隆株共进化能力。部分流行株短时间内在血清中快速繁殖,提示其条件致病后潜在的血流感染的能力。

1、 OU H Y, KUANG S N, HE X, et al. Complete genome sequence of hypervirulent and outbreak-associated Acinetobacter baumannii strain LAC-4: epidemiology, resistance genetic determinants and potential virulence factors[J]. Sci Rep,2015(5): 8643.

2、 LEES-MILLER R G, IWASHKIW J A, SCOTT N E, et al. A common pathway for O-linked protein-glycosylation and synthesis of capsule in Acinetobacter baumannii [J]. Mol Microbiol, 2013, 89(5): 816-830.

3、 RUSSO T A, LUKE N R, BEANAN J M, et al. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor [J]. Infect Immun, 2010, 78(9): 3993-4000.

4、 BOLOURCHI N , SHAHCHERAGHI F ,SHIRAZI A S,et al. Immunogenic reactivity of recombinant PKF and AbOmpA proteins as serum resistance factors against sepsis of Acinetobacter baumannii[J]. Microb Pathog, 2019(131): 9-14.

5、 SANCHEZ-LARRAYOZ A F, ELHOSSEINY N M, CHEVRETTE M G, et al. Complexity of Complement Resistance Factors Expressed by Acinetobacter baumannii Needed for Survival in Human Serum [J]. J Immunol, 2017, 199(8): 2803-2814.

6、 ROSALES-REYES R, GAYOSSO-VAZQUEZ C, FERNANDEZ-VAZQUEZ J L, et al. Virulence profiles and innate immune responses against highly lethal, multidrug-resistant nosocomial isolates of Acinetobacter baumannii from a tertiary care hospital in Mexico [J]. PLoS One, 2017, 12(8): e0182899.

7、 de BREIJ A, GADDY J, van der MEER J,et al. CsuA/BABCDE-dependent pili are not involved in the adherence of Acinetobacter baumannii ATCC19606(T) to human airway epithelial cells and their inflammatory response[J]. Res Microbiol,2009,160(3):213-218.

8、 PAKHARUKOVA N, TUITTILA M, PAAVILAINEN S, et al. Structural basis for Acinetobacter baumannii biofilm formation[J]. Proc Natl Acad Sci U S A,2018,115(21):5558-5563.

9、 EIJKELKAMP B A,HASSAN K A,PAULSEN I T,et al. Investigation of the human pathogen Acinetobacter baumannii under iron limiting conditions[J]. BMC Genomics, 2011, (12): 126.

10、 BARDBARI AM, ARABESTANI M, REZA KM, et al. Correlation between ability of biofilm formation with their responsible genes and MDR patterns in clinical and environmental Acinetobacter baumannii isolates[J]. Microb Pathog, 2017(108): 122-128.

11、 HARDING C M, PULIDO M R, DI VENANZIO G, et al. AcinetobacterPathogenic species have a functional type I secretion system and contact-dependent inhibition systems[J]. J Biol Chem, 2017, 292(22): 9075-9087.

12、 HARDING C M, HENNON S W, FELDMAN M F. Uncovering the mechanisms of Acinetobacter baumannii virulence [J]. Nat Rev Microbiol,2018,16(2):91-102.

13、 MARCHAIM D, LEVIT D, ZIGRON R, et al. Clinical and molecular epidemiology of Acinetobacter baumannii bloodstream infections in an endemic setting [J]. Future Microbiol, 2016, 12(4): 271-283.

14、 NEMEC A, KRIZOVA L, MAIXNEROVA M, et al. Acinetobacter seifertii sp. nov., a member of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolated from human clinical specimens [J]. Int J Syst Evol Microbiol, 2015, 65(Pt 3): 934-942.

15、 MEA H J , YONG P , WONG E H . An overview of Acinetobacter baumannii pathogenesis: motility, adherence and biofilm formation[J]. Microbiol Res, 2021(1):126722.

16、 K ZHOU, TANG X , WANG L , et al. An Emerging Clone (ST457) of Acinetobacter baumannii Clonal Complex 92 With Enhanced Virulence and Increasing Endemicity in South China[J]. Clin Infect Dis, 2018(suppl_2):S179-S188.

17、 HUANG G, YIN S, XIANG L, et al. Epidemiological characterization of Acinetobacter baumannii bloodstream isolates from a Chinese Burn Institute: A three-year study [J]. Burns,2016,42(7):1542-1547.

18、 WEN H, WANG K, LIU Y, et al. Population dynamics of an Acinetobacter baumannii clonal complex during colonization of patients [J]. J Clin Microbiol, 2014, 52(9): 3200-3208.

19、 CHENG V C, CHEN J H, POON R W, et al. Control of hospital endemicity of multiple-drug-resistant Acinetobacter baumannii ST457 with directly observed hand hygiene[J]. Eur J Clin Microbiol Infect Dis,2015, 34(4):713-718.

20、 NING N Z, LIU X, BAO C M, et al. Molecular epidemiology of bla OXA-23 -producing carbapenem-resistant Acinetobacter baumannii in a single institution over a 65-month period in north China [J]. BMC Infect Dis, 2017, 17(1): 14.

21、 YING J, LU J, ZONG L, et al. Molecular epidemiology and characterization of genotypes of acinetobacter baumannii isolates from regions of south china [J]. Jpn J Infect Dis, 2016, 69(3): 180-185.

22、 JIANG M, LIU L, MA Y, et al. Molecular epidemiology of multi-Drug resistant acinetobacter baumannii isolated in Shandong, China [J]. Front Microbiol, 2016(7):1687.

23、 KARAH N, SUNDSFJORD A, TOWNER K, et al. Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii[J]. Drug Resist Updat,2012,15(4):237-247.

24、 GU Y, ZHANG W, LEI J, et al. Molecular epidemiology and carbapenem resistance characteristics of Acinetobacter baumannii causing bloodstream infection from 2009 to 2018 in northwest China[J]. Front Microbiol,2022(13):983963.

25、 CDC. Antibiotic Resistance Threats in the United States, 2019[R]. Atlanta, GA: U.S. Department of Health and Human Services, 2019.

26、 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis[J]. Lancet,2022, 399(10325):629-655.

27、 de OLIVEIRA D M P,FORDE B M,KIDD T J,et al. Antimicrobial Resistance in ESKAPE Pathogens[J]. Clin Microbiol Rev, 2020,33(3):e00181-19.